It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.
Hover or tap a dot to see the filings behind that score.
Galera Therapeutics, Inc. (“Galera” or the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 (the “Quarterly Report”). As previously announced, on August 8, 2024, the Board of Directors of the Company approved a Plan of Liquidation and Dissolution (“Plan of Dissolution”), which provides for the dissolution of the Company under Delaware law and sought stockholder approval of the Plan of Dissolution at a special meeting of stockholders held on October 17, 2024 (the “Special Meeting”). At the Special Meeting, the Company’s stockholders did not approve the Plan of Dissolution. Given the Company’s lack of resources, the Company was unable to file its Quarterly Report within the prescribed time period without unreasonable effort or expense. The Company’s results of operations for the quarter ended September 30, 2024 may differ significantly from its results of operations for the quarter ended September 30, 2023 due to adverse developments that occurred with respect to the Company’s business, including the cessation of research and development activities. Due to the exploration of strategic alternatives, including the Plan of Dissolution, the Company is not able to provide an estimate of results of operations at this time
NT 10-Q, filed 2024-11-15
Galera Therapeutics, Inc. (“Galera” or the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 (the “Quarterly Report”). As previously announced, on August 8, 2024, the Board of Directors of the Company approved a Plan of Liquidation and Dissolution (“Plan of Dissolution”), which provides for the dissolution of the Company under Delaware law and sought stockholder approval of the Plan of Dissolution at a special meeting of stockholders held on October 17, 2024 (the “Special Meeting”). At the Special Meeting, the Company’s stockholders did not approve the Plan of Dissolution. Given the Company’s lack of resources, the Company was unable to file its Quarterly Report within the prescribed time period without unreasonable effort or expense. The Company’s results of operations for the quarter ended September 30, 2024 may differ significantly from its results of operations for the quarter ended September 30, 2023 due to adverse developments that occurred with respect to the Company’s business, including the cessation of research and development activities. Due to the exploration of strategic alternatives, including the Plan of Dissolution, the Company is not able to provide an estimate of results of operations at this time
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice